For instance, in the ODYSSEY OUTCOMES trial, patients with diabetes experienced a substantial reduction in MACEs when treated with PCSK9 inhibitors in combination with statins, demonstrating notable absolute risk reductions [25-28]. Here, PCSK9 is linked to diabetes mellitus.